240 results on '"Brownstone, Nicholas"'
Search Results
202. Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations.
- Author
-
Chan, Stephanie, Reddy, Vidhatha, Myers, Bridget, Thibodeaux, Quinn, Brownstone, Nicholas, and Liao, Wilson
- Subjects
- *
MACHINE learning , *DERMATOLOGY , *ELECTRONIC health records , *NOSOLOGY , *CONVOLUTIONAL neural networks - Abstract
Machine learning (ML) has the potential to improve the dermatologist's practice from diagnosis to personalized treatment. Recent advancements in access to large datasets (e.g., electronic medical records, image databases, omics), faster computing, and cheaper data storage have encouraged the development of ML algorithms with human-like intelligence in dermatology. This article is an overview of the basics of ML, current applications of ML, and potential limitations and considerations for further development of ML. We have identified five current areas of applications for ML in dermatology: (1) disease classification using clinical images; (2) disease classification using dermatopathology images; (3) assessment of skin diseases using mobile applications and personal monitoring devices; (4) facilitating large-scale epidemiology research; and (5) precision medicine. The purpose of this review is to provide a guide for dermatologists to help demystify the fundamentals of ML and its wide range of applications in order to better evaluate its potential opportunities and challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
203. Drug-Induced Alopecia Areata From Upadacitinib.
- Author
-
Chang AH, Brownstone ND, and Hsu S
- Abstract
This case report describes an unexpected occurrence of alopecia areata (AA) in a 55-year-old woman undergoing treatment with upadacitinib for atopic dermatitis. This patient developed AA approximately one year into her upadacitinib treatment for atopic dermatitis. This case highlights possible upadacitinib-induced AA, which has not been reported in the literature. Not only does this case demonstrate the typical timeline for drug-induced alopecia, but it also raises questions about whether upadacitinib can cause drug-induced alopecia., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Chang et al.)
- Published
- 2024
- Full Text
- View/download PDF
204. Boxed warnings for dermatologic JAK inhibitors: are they standardized worldwide?
- Author
-
Nguyen S, Brownstone N, and Koo J
- Subjects
- Humans, Skin Diseases chemically induced, Skin Diseases drug therapy, Janus Kinase Inhibitors adverse effects, Drug Labeling standards
- Published
- 2024
- Full Text
- View/download PDF
205. Painful nodules on the lower legs.
- Author
-
Ohanenye C, Brownstone ND, and Hsu S
- Abstract
Competing Interests: None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
206. Improving systemic therapy selection for inflammatory skin diseases: A clinical need survey.
- Author
-
Brownstone ND, Farberg AS, Litchman GH, Quick AP, Siegel JJ, Hurton LV, Goldberg MS, and Lio PA
- Abstract
Background: Empirical decisions to select therapies for psoriasis (PSO) and atopic dermatitis (AD) can lead to delays in disease control and increased health care costs. However, routine molecular testing for AD and PSO are lacking., Objective: To examine (1) how clinicians choose systemic therapies for patients with PSO and AD without molecular testing and (2) to determine how often the current approach leads to patients switching medications., Methods: A 20-question survey designed to assess clinician strategies for systemic treatment of AD and PSO was made available to attendees of a national dermatology conference in 2022., Results: Clinicians participating in the survey (265/414, 64% response rate) ranked "reported efficacy" as the most important factor governing treatment choice ( P < .001). However, 62% (165/265) of clinicians estimated that 2 or more systemic medications were typically required to achieve efficacy. Over 90% (239/265) of respondents would or would likely find a molecular test to guide therapeutic selection useful., Limitations: To facilitate ease of recall, questions focused on systemic therapies as a whole and not individual therapies., Conclusion: Clinicians want a molecular test to help determine the most efficacious drug for individual patients., Competing Interests: Dr Brownstone received a stipend paid for by Castle Biosciences, Inc. Dr Farberg is a consultant for Castle Biosciences, Inc and on the advisory board for Amgen, Boehringer Ingelheim, Eli Lilly, Galderma, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, and Sun Pharma. Drs Quick, Siegel, Hurton, and Goldberg are employees and option and stockholders for Castle Biosciences, Inc. Dr Lio reports research grants/funding from AbbVie, AOBiome, Eczema Foundation, National Eczema Association; is on the speaker's bureau for AbbVie, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, and Regeneron/Sanofi Genzyme; reports consulting/advisory boards for AbbVie, Almirall, Amyris, Arbonne, ASLAN, Bodewell, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Dermira, DermVeda, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosci, Kimberly Clark, LEO Pharma, Lipidor, L’Oreal, Menlo Therapeutics, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Theraplex, UCB, Unilever, Verrica, and Yobee Care; reports stock options with LearnSkin/Learn Health, Medable, Micreos, Modernizing Medicine, and Yobee Care. In addition, Dr Lio has a patent pending for a Theraplex product with royalties paid and is a Board member and Scientific Advisory Committee Member of the National Eczema Association. Author Litchman has no conflicts of interest to declare., (© 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
207. Readability and Health Literacy Scores for ChatGPT-Generated Dermatology Public Education Materials: Cross-Sectional Analysis of Sunscreen and Melanoma Questions.
- Author
-
Roster K, Kann RB, Farabi B, Gronbeck C, Brownstone N, and Lipner SR
- Published
- 2024
- Full Text
- View/download PDF
208. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
- Author
-
Zakria D, Brownstone N, Berman B, Ceilley R, Cronin TA Jr, Del Rosso JQ, Ferris LK, Goldenberg G, and Siegel D
- Subjects
- Humans, Prognosis, Transcriptome, Consensus, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell therapy, Skin Neoplasms diagnosis, Skin Neoplasms genetics, Skin Neoplasms therapy
- Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) is a growing health concern with a rapidly increasing incidence. Disease-specific mortality is typically preceded by a metastasis, but current staging systems have significant limitations in predicting this event. The 40-gene expression profile (40-GEP) test is a validated method of further stratifying patients based on the risk of regional or distant metastasis, but limited guidelines exist for incorporating this test into clinical practice., Objective: To review the available literature on the use of gene expression profile (GEP) testing to assess prognosis in cSCC and create consensus statements to guide dermatology clinicians on its use., Methods: A comprehensive literature search of PubMed, EMBASE, and Scopus was completed for English-language original research articles on the use of GEP testing to assess cSCC prognosis. A panel of 8 dermatologists with significant expertise in diagnosing and managing cSCC gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using the Strength of Recommendation Taxonomy (SORT) criteria., Results: The literature search produced 157 articles that met the search criteria. A thorough screening of the studies for relevance to the research question resulted in 21 articles that were distributed to the panelists for review prior to the roundtable discussion. The panel unanimously voted to adopt 7 consensus statements and recommendations, 6 of which were given a strength of "A" and 1 of which was given a strength of "C"., Conclusion: The 40-GEP test provides accurate and independent prognostic information beyond standard staging systems that only incorporate pathologic data. Incorporation of GEP testing into national guidelines can help further stratify patients based on risk of metastasis and thus may improve morbidity and mortality. J Drugs Dermatol. 2023;22(12):54-60. doi:10.36849/JDD.7691.
- Published
- 2024
- Full Text
- View/download PDF
209. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
- Author
-
Zakria D, Brownstone N, Berman B, Ceilley R, Cronin TA Jr, Del Rosso JQ, Ferris LK, Goldenberg G, and Siegel D
- Subjects
- Humans, Consensus, Prognosis, Transcriptome, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell therapy, Skin Neoplasms diagnosis, Skin Neoplasms genetics, Skin Neoplasms therapy
- Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) is a growing health concern with a rapidly increasing incidence. Disease-specific mortality is typically preceded by a metastasis, but current staging systems have significant limitations in predicting this event. The 40-gene expression profile (40-GEP) test is a validated method of further stratifying patients based on the risk of regional or distant metastasis, but limited guidelines exist for incorporating this test into clinical practice., Objective: To review the available literature on the use of gene expression profile (GEP) testing to assess prognosis in cSCC and create consensus statements to guide dermatology clinicians on its use., Methods: A comprehensive literature search of PubMed, EMBASE, and Scopus was completed for English-language original research articles on the use of GEP testing to assess cSCC prognosis. A panel of 8 dermatologists with significant expertise in diagnosing and managing cSCC gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using the Strength of Recommendation Taxonomy (SORT) criteria., Results: The literature search produced 157 articles that met the search criteria. A thorough screening of the studies for relevance to the research question resulted in 21 articles that were distributed to the panelists for review prior to the roundtable discussion. The panel unanimously voted to adopt 7 consensus statements and recommendations, 6 of which were given a strength of "A" and 1 of which was given a strength of "C"., Conclusion: The 40-GEP test provides accurate and independent prognostic information beyond standard staging systems that only incorporate pathologic data. Incorporation of GEP testing into national guidelines can help further stratify patients based on risk of metastasis and thus may improve morbidity and mortality. J Drugs Dermatol. 2023;22(12): doi:10.36849/JDD.7691e.
- Published
- 2023
- Full Text
- View/download PDF
210. Commentary: Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series.
- Author
-
Hackley M, Loesch A, Brownstone N, and Hsu S
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
211. Prescription trends of antidepressant, anxiolytic, and anticonvulsant medications among dermatologists from 2013 to 2020.
- Author
-
Roster K, Kann R, and Brownstone N
- Subjects
- Humans, Anticonvulsants therapeutic use, Dermatologists, Antidepressive Agents therapeutic use, Prescriptions, Anti-Anxiety Agents therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
212. Tinea Capitis Mimicking Alopecia Areata.
- Author
-
Loesch A, Brownstone ND, and Hsu S
- Subjects
- Humans, Alopecia, Alopecia Areata diagnosis, Tinea Capitis diagnosis
- Published
- 2023
213. Diagnosing Monkeypox: The "Doughnut Pustule" Debunked.
- Author
-
Hackley M, Brownstone ND, and Hsu S
- Subjects
- Humans, Mpox (monkeypox)
- Published
- 2023
214. Acneiform Eruption Secondary to Over-the-Counter Vitamin B12.
- Author
-
Bowden A, Ekeh O, Brownstone ND, and Hsu S
- Abstract
Treating an acneiform eruption requires the discovery of its etiology. Often, the removal of the offending agent can lead to the resolution of the eruption, resulting in an excellent prognosis. Herein, we present a rare case of a vitamin B12-induced acneiform eruption occurring in a 68-year-old female due to an over-the-counter supplement., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Bowden et al.)
- Published
- 2023
- Full Text
- View/download PDF
215. Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel.
- Author
-
Zakria D, Brownstone N, Armstrong AW, Boh EE, Koo JYM, Merola JF, Pariser D, and Lebwohl M
- Subjects
- Humans, Precision Medicine, Consensus, Dermatology, Psoriasis diagnosis, Psoriasis drug therapy
- Abstract
Background: Precision medicine utilizes an individual’s genomics to improve diagnosis, prognosis, and therapy. The joint American Academy of Dermatology and National Psoriasis Foundation 2019 guidelines recognized the need to identify biomarkers that can predict the optimal biologic agent for an individual patient. This paper examines the current state of precision medicine in dermatology and how its use can improve outcomes in psoriasis., Methods: A search of PubMed/MEDLINE using the terms precision medicine, personalized medicine, biomarkers, genomics, and dermatology was performed to identify relevant publications. An expert consensus panel was then convened to assign levels of evidence to each article using strength of recommendation taxonomy and create consensus statements requiring a two-thirds supermajority for agreement utilizing a modified Delphi approach., Results: Thirteen articles met inclusion and exclusion criteria and were assigned levels of evidence. The panel created 10 consensus statements on how precision medicine can improve patient outcomes, all of which received a unanimous (6/6) vote., Conclusion: Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing precision medicine tests such as Mind.Px can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal medication through a targeted and evidence-based approach. Zakria D, Brownstone N, Armstrong AW, et al. Integrating precision medicine into medical dermatology clinical practice: an expert consensus panel. J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.
- Published
- 2023
- Full Text
- View/download PDF
216. Targetoid Lesions, but the Diagnosis Is Not Erythema Multiforme.
- Author
-
Markeson CD, Brownstone ND, Sun CW, and Hsu S
- Subjects
- Humans, Skin pathology, Erythema Multiforme diagnosis, Erythema Multiforme pathology
- Published
- 2023
217. A trailing Scale that Is Not Erythema Annulare Centrifugum.
- Author
-
Forman JL, Brownstone ND, and Hsu S
- Subjects
- Humans, Erythema diagnosis, Skin Diseases, Genetic diagnosis
- Published
- 2023
218. Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy.
- Author
-
Zakria D, Brownstone N, Han J, Owji S, Dirr M, and Rigel D
- Subjects
- Humans, Dermoscopy methods, Dielectric Spectroscopy, Biopsy, Diagnosis, Differential, Melanoma pathology, Skin Neoplasms pathology, Dysplastic Nevus Syndrome
- Abstract
The purpose of this study was to investigate whether EIS technology can further improve correct biopsy choices beyond clinical and dermoscopic evaluation for melanoma (MM), severe dysplastic nevi (SDN) and benign PSLs. Images of 49 MMs, SDNs and benign PSLs were randomly selected from a prior study and were provided in a reader-type survey study to dermatologists to evaluate for biopsy. A total of 33,957 biopsy decisions were analyzed. Respondents significantly improved on the correct biopsy choice with the addition of dermoscopy versus clinical image alone for melanoma and severely dysplastic nevi. Respondents also showed a statistically significant improvement in correct biopsy choice beyond their dermoscopic evaluation when integrating the EIS score versus dermoscopy with clinical images for MM, SDN and benign lesions. Respondents also made fewer incorrect biopsy choices with the addition of the EIS score versus dermoscopy and clinical image for MM and benign lesions. Sub-analyses of biopsy choices were also conducted based on experience and practice type. The findings from this study demonstrate that the integration of EIS technology into PSL biopsy decisions has the potential to significantly improve the accuracy of lesion selection for biopsy beyond clinical and dermoscopic evaluation alone., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
219. How to successfully handle the initial encounter with a delusional infestation patient.
- Author
-
Brownstone N and Koo J
- Subjects
- Humans, Delusions, Dermatology, Psychotic Disorders
- Abstract
Managing a delusional patient is one of the most challenging situations experienced by dermatologists. This is exacerbated by the scarcity of psychodermatology training offered in residency and similar training programs. A few practical management tips can be easily employed in the initial visit to avoid an unsuccessful encounter. We highlight the most important management and communication techniques needed for a successful first encounter with this traditionally tricky patient population. Topics such as diagnosing primary versus secondary delusional infestation, how to prepare before entering the exam room, how to write the initial patient note, and when is the ideal time to introduce pharmacotherapy are discussed. Tips on preventing clinician burnout and creating a stress-free therapeutic relationship are reviewed., Competing Interests: Conflict of interest None declared., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
220. Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update.
- Author
-
Brownstone N, Marson JW, Zakria D, Farberg A, and Rigel D
- Subjects
- Humans, Surveys and Questionnaires, Melanoma, Cutaneous Malignant, Melanoma pathology, Melanoma therapy, Skin Neoplasms pathology, Skin Neoplasms therapy
- Abstract
This study aimed to assess the current management of melanoma from relative to present guidelines and determine changes 5 years ago. An eight-question survey was sent to practicing US dermatologists using the same methodology and questions from our JAAD study. Overall, saucerization/scoop biopsy (48%) was the most commonly used method. The most commonly chosen margin for melanoma in-situ (MMIS) removal was 6-10 mm (51% of respondents). For CMM with a depth greater than 1 mm, the most commonly chosen margins were in the 1.1-1.9 cm range (55% of respondents). More respondents referred cases of MMIS and CMM out for treatment as compared to 2016. Academic dermatologists in 2021 were 8% less likely to treat MMIS as compared to all other practice types in 2021, whereas 7% more likely to treat CMM greater than 1 mm. Academic dermatologists in 2016, as compared to 2021, were 4% more likely to treat MMIS and 19% more likely to treat CMM greater than 1 mm. A total of 91% of respondents reported having some change in their management of CMM. Our study findings suggest that a knowledge gap still exists representing a continued educational opportunity to more effectively distribute and implement CMM management guidelines., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
221. Management of delusions of parasitosis: an interview with experts in psychodermatology.
- Author
-
Brownstone N, Howard J, and Koo J
- Abstract
Delusions of parasitosis (DOP), which is also called Morgellons disease or delusional infestation, can be one of the most challenging clinical encounters in a dermatologist's practice. One reason for this is lack of education during dermatology residency and a paucity of resources for the practicing dermatologist such as specialized psychodermatology clinics for these patients. To help close this knowledge gap, an interview was conducted with 3 experts in the field of psychodermatology and their responses were recorded and edited with goal of improving care for patients suffering from DOP by educating the busy, practicing dermatologist. The experts discussed many topics regarding DOP including the difference between primary and secondary DOP, how to build a good rapport with DOP patients, why the condition is seen mostly in older woman, and which medications are effective for treatment. The interview ends with a few high-yield practical treatment tips., Competing Interests: None., (Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of Women’s Dermatologic Society.)
- Published
- 2022
- Full Text
- View/download PDF
222. Knowledge Gaps Among Dermatologists Regarding Immunotherapy for Non-melanoma Skin Cancer.
- Author
-
Brownstone N, Marson JW, Schlesinger T, and Rigel D
- Abstract
Background: Advanced nonmelanoma skin cancer (NMSC) is a sometimes unrecognized public health burden. The development of immune checkpoint inhibitors (ICIs), such as those affecting programmed cell death protein-1 (PD-1), have dramatically changed the management of advanced NMSC. Dermatologists need to be knowledgeable about these therapies given their key role in diagnosing, treating, and comanaging NMSC. The purpose of this study was to assess the knowledge base and identify knowledge gaps that dermatologists may have regarding ICIs and assess advanced NMSC referral patterns., Methods: A 10-question survey was emailed to United States-based dermatologists in July 2021 assessing knowledge of ICI therapy and referral patterns for metastatic cutaneous squamous cell carcinoma (mcSCC) or locally advanced basal cell carcinoma (laBCC) management., Results: At their current knowledge level, respondents averaged 40.6 out of 100 (95% CI [35.1, 46.0]) when asked how comfortable they feel counseling a patient on the risks and benefits of an ICI. Seventy-one percent reported that having more information about treatment for mcSCC or laBCC would be helpful in their practice. Being in practice for less than 10 years was not significantly associated with desiring more information about treatment. The respondents reported that the highest number of annual average referrals out for mcSCC or laBCC were made to Mohs surgeons. Fifty-four percent of respondents received referrals for mcSCC or laBCC, and of the providers receiving referrals, 40 percent of them came from general dermatology., Conclusion: These results demonstrate that a knowledge gap exists for dermatologists in treating mcSCC and laBCC with immunotherapy. There is a need among all dermatologists, regardless of years in practice, to receive this information., Competing Interests: DISCLOSURES: Dr. Schlesinger reports the following disclosures: AbbVie Consulting (Honoraria)/Grant/Research Funding Acrutis Premier Research Grant/Research Funding Allergan Consulting (Honoraria)/Advisory Board/Grant/Research Funding Almirall Speaker's Bureau/Advisory Board (Honoraria)/Consulting Amgen Advisory Board Anterios Grant/Research Funding AOBiome Grant/Reasearch Funding Astellas Pharma US, Inc Grant/Research Funding Athenex Grant/Research Funding Bioderma (Honoraria) Advisory Board (Honoraria) Biofrontera Grant/Research Funding Biofrontera AG Advisory Board (Honoraria) BioPharmx Consulting Biorasi Grant/Research Funding Boehringer Ingerlheim Grant/Research Funding Brickell Biotech Grant/Research Funding Bristol-Meyers Squibb Grant/Research Funding/Consulting (Honoraria) Cara Therapeutics Grant/Research Funding Castle BioScience Grant/Research Funding/Consulting (Honoraria) Celgene Grant/Research Funding/Advisory Board Centocor Ortho Biotech (Now Janssen Biotech) Grant/Research Funding ChemoCentryx Grant/Research Funding CMS Aesthetics DCME Consulting Coherus Biosciences Grant/Research Funding Concert Pharmaceutical Grant/Research Funding Corrona Grant/Research Funding Cutanea Life Sciences Grant/Research Funding Dermavant Grant/Research Funding Dermira Grant/Research Funding DT Pharmacy & DT Collagen (Melasma) Grant/Research Funding DUSA/ Sun Pharma Speaker Bureau EPI Health Grant/Research Funding/Consulting (Honoraria)/Speaker's Bureau Foundation for Research and Education in Dermatology (Fred) Consulting (Honoraria) Galderma (Nestle) Grant/Research Funding/Consulting (Honoraria) Greenway Therapeutix Advisory Board (No Compensation received) Janssen Pharmaceuticals, Inc Grant/Research Funding Kiniksa Grant/Research Funding Kintor Consulting Leo Grant/Research Funding Lilly Grant/Research Funding/Consulting (Fees) MED Learning Group CME Program (Aug-Oct 2019) Merz Grant/Research Funding/Consulting (Honoraria) MJH Associates OncLive SCC Insights Filming/Stacy Jaffe Nestle Skin Health Grant/Research Funding Nextphase Consulting Nimbus Grant/Research Funding Novartis Grant/Research Funding/Consulting (Honoraria) Ortho Dermatologics Consulting, Fees Pfizer Grant/Research Funding Pharmatecture Consulting Pierre Fabre Consulting, Fees Plasmed Consulting, Fees Processa Grant/Research Funding Prolacta Bioscience Consulting Pulse BioSciences Grant/Research Funding Regeneron Grant/Research Funding/Consulting (Fees)/Speaker's Bureau (Honoraria) Remedly, Inc Advisory Board (Stock Options) Sanofi Genzyme Grant/Research Funding/Speaker's Bureau Sisaf Grant/Research Funding Skinceuticals/L'Oreal Consulting, Fees Sun Pharma Consulting/Speaker's Bureau (Honoraria) Trevi Grant/Research Funding UCB Consulting Verrica Consulting. Dr. Rigel serves as a consultant, advisory board member and speaker for Castle Biosciences, Inc. Dr. Brownstone and Dr. Marson have no disclosures., (Copyright © 2022. Matrix Medical Communications. All rights reserved.)
- Published
- 2022
223. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
- Author
-
Wisco OJ, Marson JW, Litchman GH, Brownstone N, Covington KR, Martin BJ, Quick AP, Siegel JJ, Caruso HG, Cook RW, Winkelmann RR, and Rigel DS
- Subjects
- Gene Expression Profiling methods, Humans, Neoplasm Staging, Prognosis, Retrospective Studies, Transcriptome, United States, Melanoma, Cutaneous Malignant, Melanoma pathology, Skin Neoplasms pathology
- Abstract
Cutaneous melanoma (CM) survival is assessed using averaged data from the American Joint Committee on Cancer 8th edition (AJCC8). However, subsets of AJCC8 stages I-III have better or worse survival than the predicted average value. The objective of this study was to determine if the 31-gene expression profile (31-GEP) test for CM can further risk-stratify melanoma-specific mortality within each AJCC8 stage. This retrospective multicenter study of 901 archival CM samples obtained from patients with stages I-III CM assessed 31-GEP test predictions of 5-year melanoma-specific survival (MSS) using Kaplan-Meier and Cox proportional hazards. In stage I-III CM population, patients with a Class 2B result had a lower 5-year MSS (77.8%) than patients with a Class 1A result (98.7%) and log-rank testing demonstrated significant stratification of MSS [χ2 (2df, n = 901) = 99.7, P < 0.001). Within each stage, 31-GEP data provided additional risk stratification, including in stage I [χ2 (2df, n = 415) = 11.3, P = 0.004]. Cox regression multivariable analysis showed that the 31-GEP test was a significant predictor of melanoma-specific mortality (MSM) in patients with stage I-III CM [hazard ratio: 6.44 (95% confidence interval: 2.61-15.85), P < 0.001]. This retrospective study focuses on Class 1A versus Class 2B results. Intermediate results (Class 1B/2A) comprised 21.6% of cases with survival rates between Class 1A and 2B, and similar to 5-year MSS AJCC stage values. Data from the 31-GEP test significantly differentiates MSM into lower (Class 1A) and higher risk (Class 2B) groups within each AJCC8 stage. Incorporating 31-GEP results into AJCC8 survival calculations has the potential to more precisely assess survival and enhance management guidance., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
224. TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.
- Author
-
Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, and Liao WJ
- Abstract
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic therapies are approved. Over the past decade, studies have documented the higher efficacy of IL-17 and IL-23 inhibitors for the treatment of psoriasis compared to the TNF-alpha inhibitors and ustekinumab, an IL-12/23 inhibitor. Despite this, there remains an important role for the use of TNF-alpha inhibitors and ustekinumab in the treatment of psoriasis. Here, we review how considerations of infection and malignancy risk, patient demographics, treatment resistance, and co-morbidities may make certain TNF-alpha inhibitors or ustekinumab an excellent choice for therapy in particular patient subgroups.
- Published
- 2022
- Full Text
- View/download PDF
225. Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology.
- Author
-
Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, and Liao WJ
- Subjects
- Adalimumab therapeutic use, Alopecia Areata drug therapy, Antibodies, Monoclonal therapeutic use, Certolizumab Pegol therapeutic use, Dermatitis, Atopic drug therapy, Etanercept therapeutic use, Granuloma Annulare drug therapy, Hidradenitis Suppurativa drug therapy, Humans, Infliximab therapeutic use, Lupus Erythematosus, Systemic drug therapy, Pemphigus drug therapy, Pyoderma Gangrenosum drug therapy, Sarcoidosis drug therapy, Stevens-Johnson Syndrome drug therapy, Ustekinumab therapeutic use, Dermatology, Interleukin Inhibitors therapeutic use, Off-Label Use, Tumor Necrosis Factor Inhibitors therapeutic use
- Abstract
TNF-a inhibitors, which include adalimumab, infliximab, etanercept, certolizumab, and golimumab, and IL-12/23 inhibitor, ustekinumab, have been widely used as a U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. Outside of psoriasis, high levels of TNF-a had also been found in several skin diseases including hidradenitis suppurativa. IL-12 and IL-23 play important role in the pathogenesis of SLE, alopecia areata, and vitiligo. This paper reviews the off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in skin disorders.
- Published
- 2021
- Full Text
- View/download PDF
226. Improving care for delusional infestation patients: What can dermatologists learn from an entomologist?
- Author
-
Cheng C, Ridge G, Koo J, and Brownstone N
- Subjects
- Animals, Communication, Humans, Pets, Professional-Patient Relations, Self-Injurious Behavior psychology, Specimen Handling, Time Factors, Delusional Parasitosis psychology, Delusional Parasitosis therapy, Dermatologists education, Entomology
- Abstract
Delusional Infestation (DI), represents one of the most difficult patient encounters that dermatology practitioners may experience. It is common for DI patients to doctor shop. Thus, dermatologists are one of several disciplines that may encounter DI patients in their practices. Others include veterinarians, epidemiologists, emergency departments, mental health practitioners, and entomologists. In this article, entomologist, Dr. Gale E. Ridge, with extensive DI experience, was interviewed to find out what an entomologist's perspective has been and what we, the dermatology providers, can learn from that. This is followed by a discussion by the dermatology experts on how the experience of entomologists compares to our experience and what we can learn from them.
- Published
- 2021
- Full Text
- View/download PDF
227. Innovations in translational research in dermatology: minimally invasive methods for biosample acquisition.
- Author
-
Hadeler E, Mosca M, Hong J, Brownstone N, Liao W, and Bhutani T
- Subjects
- Biopsy adverse effects, Biopsy instrumentation, Biopsy methods, Blister, Dermoscopy methods, Extracellular Fluid, Hair Removal methods, Humans, Patch Tests methods, Suction methods, Tissue Adhesives, Dermatology methods, Translational Research, Biomedical methods
- Abstract
Translational research has improved patient care over the last decade. In dermatology, this research often requires human tissue for laboratory analysis. The skin biopsy remains the gold standard for tissue acquisition, but the procedure comes with a small risk of bleeding and infection. It also causes scarring and anxiety in certain populations. These risks and concerns may affect participation rates in translational studies, which can require multiple biopsies. Minimally invasive procedures may mitigate these risks and concerns. We queried the PubMed database for all minimally invasive technologies studied as of May 2021. Of the 53 articles reviewed, we identified 13 unique, minimally invasive methods for tissue biosample acquisition. Herein, we describe each sampling method, biosample type analyzed, disease target, molecular application, procedure, quantity of obtained biosample, purpose, and required equipment. We organize this information into a comprehensive chart. We then synthesize this information into another table that compares the pros and cons of each intervention. We found that tape stripping, suction blistering, hair plucking, microbiopsy, and microneedle patching provide a variety of useful biosample types for laboratory analysis. In translational research, these technologies have the potential to replace more invasive methods like the punch biopsy, likely improving participation in studies.
- Published
- 2021
- Full Text
- View/download PDF
228. Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline.
- Author
-
Bui A, Liu J, Hong J, Hadeler E, Mosca M, Brownstone N, and Liao W
- Abstract
Background: Despite numerous genome-wide association studies conducted in psoriasis and psoriatic arthritis, only a small fraction of the identified genes has been therapeutically targeted., Objective: We sought to identify and analyze potential therapeutic targets for psoriasis and psoriatic arthritis (PsA) using the priority index (Pi), a genetics-dependent drug target prioritization approach., Methods: Significant genetic variants from GWAS for psoriasis, PsA, and combined psoriatic disease were annotated and run through the Pi pipeline. Potential drug targets were identified based on genomic predictors, annotation predictors, pathway enrichment, and pathway crosstalk., Results: Several gene targets were identified for psoriasis and PsA that demonstrated biological associations to their respective diseases. Some are currently being explored as potential therapeutic targets (i.e. ICAM1, NF-kB, REV3L, ADRA1B for psoriasis; CCL11 for PsA); others have not yet been investigated (i.e. LNPEP, LCE3 for psoriasis; UBLCP1 for PsA). Additionally, many nodal points of potential intervention were identified as promising therapeutic targets. Of these, some are currently being studied such as TYK2 for psoriasis, and others have yet to be explored (i.e. PPP2CA, YAP1, PI3K, AKT, FOXO1, RELA, CSF2, IFNGR1, IFNGR2 for psoriasis; GNAQ, PLCB1, GNAI2 for PsA)., Conclusion: Through Pi, we identified data-driven candidate therapeutic gene targets and pathways for psoriasis and PsA. Given the sparse PsA specific genetic studies and PsA specific drug targets, this analysis could prove to be particularly valuable in the pipeline for novel psoriatic therapies., Competing Interests: Conflicts of Interest: Dr. Liao has received research grant support from Abbvie, Amgen, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, and TRex Bio.
- Published
- 2021
- Full Text
- View/download PDF
229. Cultural and biological factors in body dysmorphic disorder in East Asia.
- Author
-
Hong J, Hadeler E, Mosca M, Brownstone N, Bhutani T, and Koo J
- Subjects
- Cross-Cultural Comparison, Cultural Characteristics, Esthetics, Ethnicity, Asia, Eastern epidemiology, Humans, Prevalence, Body Dysmorphic Disorders epidemiology, Body Dysmorphic Disorders ethnology, Body Dysmorphic Disorders psychology
- Abstract
Body dysmorphic disorder (BDD) can cause severe distress and impairment in many important areas of functioning. Although BDD has been well studied in Western populations, there is limited information on BDD in other cultures. In this review, we discuss the prevalence and presentation of BDD in East Asian countries and the significance of conducting further research in this particular group.
- Published
- 2021
- Full Text
- View/download PDF
230. Seeing the Treatment of Psoriasis in a New Light: A Novel Medical Device Utilizing Localized Coal Tar and Narrowband UVB for Targeted Treatment of Plaque Psoriasis.
- Author
-
Brownstone ND, Bridges A, Bhutani T, Anderson E, and Sugarman J
- Subjects
- Combined Modality Therapy, Humans, Pilot Projects, Ultraviolet Therapy, Coal Tar, Psoriasis diagnosis, Psoriasis drug therapy, Psoriasis radiotherapy
- Abstract
Given the high costs of systemic psoriasis therapies, studies have also shown that phototherapy achieves significant cost savings by replacing or delaying drug-based systemic treatment in patients with moderate to severe disease. However, this modality is often underutilized mainly due to the lack of phototherapy treatment centers across the country. Home phototherapy was designed to fill this treatment gap and allow patients to be treated with phototherapy despite living in areas that may not have a formal treatment facility. Inspired by the Goeckerman regimen, a preliminary pilot study showed that a novel, home phototherapy device utilizing a mobile phone-controlled L.E.D UVB light source and an occlusive hydrogel patch containing coal tar was superior to control as well as both NB-UVB alone and a coal tar dressing alone.Visit the Psoriasis Resource Center for more on this topic.
- Published
- 2021
- Full Text
- View/download PDF
231. Biologic Treatments of Psoriasis: An Update for the Clinician.
- Author
-
Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, and Koo J
- Abstract
The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care., Competing Interests: Wilson Liao reports grants from Amgen, Novartis, Janssen, Leo Pharma, Sanofi, TRex Bio, and Regeneron. Tina Bhutani is currently an investigator for Abbvie, Galderma, Pfizer and Regeneron. She has served as an advisor for Abbvie, Boehringer-Ingelheim, Bristol-Myers-Squibb, Clarify, Leo, Lilly, Novartis, Pfizer and Sun Pharma. John Koo reports being a speaker and adviser for Amgen, Abbvie, Eli Lilly, Sun Pharmaceutical, Novartis, Ortho Dermatologic, Janssen and UCB. The authors report no other potential conflicts of interest for this work., (© 2021 Brownstone et al.)
- Published
- 2021
- Full Text
- View/download PDF
232. The use of Goeckerman therapy in managing erythrodermic psoriasis resistant to multiple medications.
- Author
-
Myers B, Reddy V, Brownstone N, Chan S, Thibodeaux Q, and Koo J
- Subjects
- Combined Modality Therapy, Dermatitis, Exfoliative complications, Drug Resistance, Female, Humans, Male, Psoriasis complications, Coal Tar therapeutic use, Dermatitis, Exfoliative therapy, Psoriasis therapy, Ultraviolet Therapy
- Abstract
Erythrodermic psoriasis is a relatively rare, more dangerous inflammatory variant of psoriasis associated with high morbidity and mortality. It can be exceptionally challenging to manage, defeating even the most experienced dermatologist's arsenal of treatment strategies. Goeckerman therapy, a regimen of ultraviolet B phototherapy and crude coal tar, has demonstrable efficacy in severe and recalcitrant plaque-type psoriasis. However, its utility in erythrodermic psoriasis has not been explored within the dermatology literature. Herein, we present a patient with a long-standing history of erythrodermic psoriasis refractory to eleven treatment modalities including four biologic agents, who had his erythroderma 'turned around' following Goeckerman therapy. 'Turned around' is used to describe dramatically reducing a patient's cutaneous inflammation so that previously recalcitrant disease can now respond to maintenance therapy. The importance of a one to three week 'cool down' period of topical corticosteroid therapy prior to phototherapy or crude coal tar use is highlighted in this case as well. Although Goeckerman therapy is no longer regularly used, it remains one of the most efficacious treatments available for intractable psoriasis, attracting patients from all over the country desperate for symptom relief. This case suggests it may be useful in 'turning around' extremely difficult-to-treat erythrodermic psoriasis as well.
- Published
- 2021
233. Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review.
- Author
-
Myers B, Thibodeaux Q, Reddy V, Chan S, Brownstone N, Liao W, and Bhutani T
- Abstract
The management of psoriatic disease in human immunodeficiency virus (HIV)-positive patients is challenging. Psoriasis in HIV-positive patients is often severe, progressive, and resistant to first- and second-line therapies, including topical treatments, phototherapy, highly active antiretroviral therapy (HAART), and oral retinoids. Other systemic agents used to treat psoriasis, such as methotrexate and cyclosporine, are immunosuppressants and thus many dermatologists may not feel comfortable prescribing them to HIV-positive patients who are already immunocompromised. Biologic agents, which target specific aspects of overactive immune pathways in psoriasis, have revolutionized the management of moderate-to-severe psoriasis. However, data is limited regarding their safety and efficacy in HIV-positive patients., Objective: Report four cases of HIV-positive patients managed on biologic therapy and summarize the cases of psoriasis in HIV-positive patients managed on biologic therapy that have been published in dermatologic literature to date., Methods: We searched PubMed and Embase databases using the terms HIV and psoriasis or HIV and psoriatic arthritis combined with one of the eleven biologics currently approved for treating psoriasis., Results: We identified 48 cases of anti-psoriasis biologic therapy (including adalimumab, infliximab, etanercept, ustekinumab, and guselkumab) in HIV-positive patients and added four. While data is limited, the evidence available suggests biologic agents are safe and efficacious in moderate-to-severe psoriasis and may even have a favorable effect on CD4 and HIV viral counts when used with concomitant HAART., Conclusion: Further research would be helpful to establish practical guidelines for the use of anti-psoriasis biologic therapy in the HIV population, including that of newer agents., Competing Interests: Declaration of conflicting interest: Authors Bridget Myers, Vidhatha Reddy, Stephanie Chan, Dr. Nicholas Brownstone and Dr. Quinn Thibodeaux have no conflicts of interest to disclose.
- Published
- 2021
- Full Text
- View/download PDF
234. Prescribing Isotretinoin for Transgender Patients: A Call to Action and Recommendations.
- Author
-
Sanchez DP, Brownstone N, Thibodeaux Q, Reddy V, Myers B, Chan S, and Bhutani T
- Subjects
- Abnormalities, Drug-Induced etiology, Acne Vulgaris drug therapy, Acne Vulgaris etiology, Adult, Dermatologic Agents administration & dosage, Dermatology legislation & jurisprudence, Dermatology standards, Female, Gender Identity, Humans, Isotretinoin administration & dosage, Male, Practice Guidelines as Topic standards, Sex Reassignment Procedures adverse effects, Sex Reassignment Procedures methods, Testosterone administration & dosage, Testosterone adverse effects, Abnormalities, Drug-Induced prevention & control, Dermatologic Agents adverse effects, Drug Prescriptions standards, Isotretinoin adverse effects, Transgender Persons legislation & jurisprudence
- Abstract
Case Scenerio: A 26-year-old patient presents to the dermatology clinic with severe nodulocystic scarring acne. The patient identifies as a transgender male and notes that he has been receiving hormone replacement therapy for the past 4 years with weekly intramuscular testosterone injections.
- Published
- 2021
- Full Text
- View/download PDF
235. High-dose doxepin for the treatment of chronic, intractable scalp pruritus.
- Author
-
Chan S, Reddy V, Myers B, Brownstone N, Thibodeaux Q, and Koo J
- Abstract
Competing Interests: None disclosed.
- Published
- 2020
- Full Text
- View/download PDF
236. Extraocular sebaceous carcinoma as a rapidly growing back mass: a case report.
- Author
-
Lipman K, Franck P, Brownstone N, and Ascherman J
- Subjects
- Adenocarcinoma, Sebaceous diagnosis, Adenocarcinoma, Sebaceous diagnostic imaging, Aged, Back, Diagnosis, Differential, Humans, Magnetic Resonance Imaging, Male, Sebaceous Gland Neoplasms diagnosis, Sebaceous Gland Neoplasms diagnostic imaging, Skin Diseases diagnosis, Adenocarcinoma, Sebaceous pathology, Sebaceous Gland Neoplasms pathology
- Abstract
Sebaceous carcinoma is a rare cutaneous malignancy that frequently mimics other dermatologic conditions. Extraocular subtypes are uncommon, but when present are frequently located in the head and neck region. Herein, we present a patient with a rapidly growing upper back mass eventually diagnosed as sebaceous carcinoma and managed with wide surgical excision. Currently, sparse literature exists to guide management of such patients. This case highlights not only the diagnostic challenges of sebaceous carcinoma, but also the need for further studies to investigate therapeutic interventions and long-term outcomes.
- Published
- 2020
237. Office-Based Surgical Intervention for Hidradenitis Suppurativa (HS): A Focused Review for Dermatologists.
- Author
-
Saylor DK, Brownstone ND, and Naik HB
- Abstract
Easily accessible office-based procedures that require minimal resources may facilitate timely surgical management of hidradenitis suppurativa (HS). This review focuses on excision and unroofing as two surgical HS treatments that can be tailored to the outpatient setting. Fifty-five articles were included in our review, representing 3914 patients. The majority were retrospective studies (58%, n = 32), and the studies reported data both across patients and by number of treated lesions. Recurrence rates for unroofing (14.5%) were found to be half that of excision (30%) across patients (p = 0.015) and slightly lower across lesions [20% recurrence vs 26% for excision (p = 0.023)]. Complication rates at the lesion level were also significantly associated with procedure, with rates after excision more than double those after roofing (26% vs. 12%, p < 0.001). The complication rate after combined medical and surgical therapy did not differ between procedures. Studies also suggest that continuing medical therapy in the perioperative period may be associated with improved recurrence rates, although delayed wound healing with biologic therapy has been reported. The existing data are limited by low-quality uncontrolled studies with small sample sizes, variable reporting of outcomes, and lack of uniform definitions for recurrence and remission. Further systematic prospective studies are needed to better compare complication and recurrence rates across these procedures in HS, especially in the context of concomitant medical therapy.
- Published
- 2020
- Full Text
- View/download PDF
238. Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
- Author
-
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, and Liao W
- Abstract
The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.
- Published
- 2020
- Full Text
- View/download PDF
239. Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.
- Author
-
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, and Liao W
- Abstract
With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here., (© The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
240. Apocrine adenocarcinoma in the setting of apocrine hidrocystoma of the leg.
- Author
-
Toyoda Y, Franck P, Brownstone ND, Lieberman M, Magro CM, and Otterburn DM
- Subjects
- Adenocarcinoma complications, Hidrocystoma complications, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive radiotherapy, Male, Middle Aged, Sweat Gland Neoplasms complications, Whole-Body Irradiation, Adenocarcinoma pathology, Hidrocystoma pathology, Leg, Sweat Gland Neoplasms pathology
- Abstract
Apocrine hidrocystoma is a benign, cystic lesion often presenting in the periorbital region. Apocrine adenocarcinoma is the rare, malignant counterpart occurring mainly in the axilla and anogenital region. There is a paucity of literature on both entities and co-occurrence has been reported in only 5 cases. We present the case of a 48-year-old man with a history of total body irradiation for chronic myelocytic leukemia, diabetes mellitus, and obesity who presented with a calf mass of two years' duration. Epidermal inclusion cyst was presumed and excisional biopsy was carried out. Pathologic analysis revealed apocrine adenocarcinoma in the setting of a precursor apocrine hidrocystoma. Our patient's unique altered immunity and the direct effects of irradiation on the local microenvironment may have resulted in his rare presentation of co-occurrence of apocrine adenocarcinoma within an existing apocrine hidrocystoma. To our knowledge, our patient is the first reported patient with this presentation in the lower extremity.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.